NFE2L2 and lung adenocarcinoma: Initially discovered in lung cancer [52], gain-of-function mutations in NFE2L2 (the gene encoding NRF2) or loss-of-function mutations in KEAP1 were found to be frequently acquired by cancers [53], with a frequency of about 20% in lung adenocarcinoma (LUAD) [54].